All public logs

Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

• 19:46, 28 January 2015 Gloria Picoy talk contribs uploaded a new version of File:Acitretin 10 mg FDA package label.png
• 19:46, 28 January 2015 Gloria Picoy talk contribs uploaded File:Acitretin 10 mg FDA package label.png
• 19:01, 28 January 2015 Gloria Picoy talk contribs uploaded File:Acitretin structural formula.png
• 17:00, 28 January 2015 Gloria Picoy talk contribs uploaded File:Vorinostat structure.png
• 16:53, 28 January 2015 Gloria Picoy talk contribs uploaded File:Vorinostat 100 mg.png
• 16:52, 28 January 2015 Gloria Picoy talk contribs uploaded File:Vorinostat FDA package label.png
• 16:46, 28 January 2015 Gloria Picoy talk contribs uploaded File:Vorinostat Baseline Patient Characteristics.png
• 16:39, 28 January 2015 Gloria Picoy talk contribs uploaded File:Vorinostat structural formula.png
• 16:33, 28 January 2015 Gloria Picoy talk contribs uploaded File:Vorinostat Clinical or Laboratory Adverse Reactions Occurring in CTCL Patients.png
• 15:29, 28 January 2015 Gloria Picoy talk contribs uploaded File:Pyrimethamine 25 mg.png
• 15:26, 28 January 2015 Gloria Picoy talk contribs uploaded File:Pyrimethamine FDA package label.png
• 15:25, 28 January 2015 Gloria Picoy talk contribs uploaded File:Pyrimethamine structure.png
• 14:48, 28 January 2015 Gloria Picoy talk contribs uploaded File:Pyrimethamine structural formula.png
• 06:44, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate structure.png
• 06:42, 28 January 2015 Gloria Picoy talk contribs uploaded a new version of File:Triptorelin pamoate 22.5 mg Adverse Reactions Reported by 5% or More of Patients During Treatment.png
• 06:41, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate 22.5 mg Adverse Reactions Reported by 5% or More of Patients During Treatment.png
• 06:39, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate 11.25 mg Treatment-Related Adverse Reactions Reported by 1% or More of Patients During Treatment.png
• 06:36, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate Treatment-Related Adverse Reactions Reported by 1% or More of Patients During Treatment.png
• 06:35, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate 22.5 mg FDA package label.png
• 06:34, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate 11.25 mg FDA package label.png
• 06:29, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate 22.5 mg.png
• 06:28, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate 11.25 mg.png
• 06:26, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate 3.75 mg FDA package label.png
• 06:25, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate 3.75 mg.png
• 06:14, 28 January 2015 Gloria Picoy talk contribs uploaded File:Summary of triptorelin pamoate Clinical Studies.png
• 06:07, 28 January 2015 Gloria Picoy talk contribs uploaded File:Triptorelin pamoate structural formula.png
• 04:45, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc structure.png
• 04:38, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Trial Outcome at Week 96 Using Enhanced Sensitivity Assay.png
• 04:35, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Demographic and Baseline Characteristics of Subjects in Trial A4001026.png
• 04:32, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Outcomes of Randomized Treatment at Week 48 Trials A4001027 and A4001028.png
• 04:29, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Demographic and Baseline Characteristics of Subjects in Trials A4001027 and A4001028.png
• 04:22, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Trial in Treatment‑Naive Subjects.png
• 04:18, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Laboratory Abnormalities.png
• 04:17, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Trials in Treatment-Experienced Subjects.png
• 04:07, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc 300 mg.png
• 04:06, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc 150 mg.png
• 04:05, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc 300 mg FDA package label.png
• 04:04, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc 150 mg FDA package label.png
• 03:38, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Development of Resistance to Maraviroc or Efavirenz and Background Drugs in Antiretroviral Treatment-Naive Trial.png
• 03:33, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Mean Maraviroc Pharmacokinetic Parameters.png
• 03:29, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Exposure Response Relationship in Treatment-Naive Subjects.png
• 03:27, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc Exposure Response Relationship in Treatment-Experienced Subjects.png
• 03:24, 28 January 2015 Gloria Picoy talk contribs uploaded File:Maraviroc structural formula.png
• 20:43, 26 January 2015 Gloria Picoy talk contribs uploaded File:Decitabine 50 mg.png
• 20:41, 26 January 2015 Gloria Picoy talk contribs uploaded File:Decitabine structure.png
• 20:35, 26 January 2015 Gloria Picoy talk contribs uploaded File:Decitabine Single-arm Studies.png
• 20:33, 26 January 2015 Gloria Picoy talk contribs uploaded File:Decitabine Baseline Response Criteria for Phase 3 MDS Trial.png
• 20:31, 26 January 2015 Gloria Picoy talk contribs uploaded File:Decitabine Baseline Demographics and Other Patient Characteristics.png
• 20:27, 26 January 2015 Gloria Picoy talk contribs uploaded File:Decitabine adverse reactions table 2.png
• 20:23, 26 January 2015 Gloria Picoy talk contribs uploaded File:Decitabine adverse reactions.png